Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Rapid Nutrition’s deal with major US nutrition supplement retailer GNC is a harbinger of greater things to come

Rapid Nutrition is tapping into a potentially huge market
Rapid Nutrition’s deal with major US nutrition supplement retailer GNC is a harbinger of greater things to come
A selection from Rapid Nutrition's product range

“We have a five year exclusive deal with GNC,” says Simon St Ledger of Rapid Nutrition PLC (SIX:RAP).

For those not in the know, GNC, otherwise known as General Nutrition Corporation Holdings (NYSE:GNC), is one of the world’s leading retailers of nutritional supplements.

WATCH: Rapid Nutrition is moving from licensing model to a distribution model

It’s almost 30 times the size of Rapid Nutrition in terms of market capitalisation, and boasts a significant footprint of stores across the US.

But both companies recognise that as far as global markets are concerned, they are only beginning to scratch the surface.

Nutritional supplements can serve a variety of purposes, but one of them is what is euphemistically termed by analysts as “weight management.”

Rapid’s house broker Hybridan notes that Grand View Research, Inc expects the global weight management market to have more than doubled its 2016 value to over US$442bn by the end of 2025.

This growth is what underpins high double digit price/earnings multiples in the sector, and private deals involving Rapid’s peers have seen take out multiples of over 5x. The company continues to explore the possibility of also listing its ordinary shares on a UK stock exchange.

The US will be key to this growth, and trends towards combatting obesity across the western world will also play a part. But another crucial area of growth will be in East Asia and China in particular.

“It’s a massive market,” say St Ledger.

GNC deal ideal platform

And Rapid Nutrition aims to address it in as broad a manner as possible. It has a suite of products based around its proprietary brand Leisa’s Secret. These include System LS, which St Ledger describes as the company’s flagship, and which is sold under a marketing message that involves healthy nutrition for people with busy active lives.

“We target the mass market,” says St Ledger. “The everyday mum and dad.”

The GNC deal is the latest step on a path to growth that will involve Rapid Nutrition expanding its distribution, developing more products, and increasing brand penetration.

The GNC deal is an ideal platform on which to base this growth. Under the terms of the deal, Rapid Nutrition will gain access for its products to GNC’s network of 7,000-plus stores in the USA. It will also have the rights to distribute and market GNC products in Australia, while in the UK, market penetration will be directly undertaken by Rapid itself.

And, although it’s early days, the numbers are already reflecting this growth potential. In 2017, Rapid Nutrition’s revenues grew by 30%.

And for 2018, St Ledger says the company’s revenues are “tracking well.”

There should be a further significant boost when the effects of the GNC deal start flowing through, and the penetration into China starts to gain real traction.

View full RAP profile View Profile

Rapid Nutrition PLC Timeline

Related Articles

Flow chart of the Hazer Process
March 21 2018
The Hazer Process could disrupt the $100 billion hydrogen production market.
An illustration of the tools Velpic uses in providing education and incident management
March 22 2018
Velpic has just signed its first NowForce client in Australia.
electric vehicle charging
July 04 2018
AMP wants to add 25 sites in Greater London and extend its reach into the North-West around Liverpool and Manchester

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use